Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 109

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 109
---
                           |     |              |           |   |     |      |         |   |
| Horizon 2020 Grant                                           |     |              |     2,306 |   |     |      |       - |   |
| Other research and development expenses                      |     |              |      (232 | ) |     |      |    (806 | ) |
| General and administrative expenses                          |     |              |      (712 | ) |     |      |  (1,125 | ) |
| Operating (profit) loss                                      |     |              |     1,362 |   |     |      |  (1,931 | ) |
| Financial income (expense), net:                             |     |              |           |   |     |      |         |   |
| Changes in fair value of convertible notes                   |     |              |     3,483 |   |     |      |  (2,019 | ) |
| Changes in fair value of warrant liability                   |     |              |       463 |   |     |      |      62 |   |
| Other financing income (expense),                            
 net                                                          |     |              |       (77 | ) |     |      |    (244 | ) |
| Net income (loss) and comprehensive income (loss)            |     |              |     5,231 |   |     |      |  (4,132 | ) |
| Basic and diluted net income (loss) per share                |     |              |      1.87 |   |     |      |  (24.09 | ) |
| Weighted average number of ordinary shares used in computing 
 basic and diluted net income / (loss) per share              |     |              | 2,765,850 |   |     |      | 173,508 |   |

<div align='center'>64</div>

Year Ended December 31, 2024 Compared to Year Ended December 31, 2023

Research and development expenses

Research and development
expenses decreased by approximately $2,880 thousand or 357.3%, to approximately income of $2,074 thousand for the year ended December
31, 2024, compared to $806 thousand for the year ended December 31, 2023. The decrease resulted mainly from the Horizon 2020 Grant, and
from a decrease in subcontractors’ expenses due to lower research and development activity during 2024.

General and administrative expenses